84-1175-60　IGFBP-7 (Insulin-like Growth Factor-binding Protein 7, IBP-7, IGF-binding Protein 7, IBP7, GFBP-rP1, MAC25 Protein, PGI2-stimulating Factor, Prostacyclin-stimulating Factor, Tumor-derived Adhesion Factor, TAF, IGFBP7, MAC25, PSF) 100ul　I7661-17A2

特徴

• Unlike insulin, both IGF-I and IGF-II circulate in plasma tightly bound to specific binding proteins.
• Two major forms of IGF-binding proteins have been identified in human plasma, a low molecular weight form and a high molecular weight form.
• The low molecular weight IGF-binding protein (IGFBP1) is synthesized in liver, secretory endometrium, and decidua.
• It binds both IGF I and IGF II with high affinity.
• Insulin-like growth factor binding protein-1 (IGFBP-1 ~30kD; also known as IBP1 or placental protein 12, or IGF-BP25; chromosome 7p14-p12)) is a member of the superfamily of insulin-like growth factor (IGF) binding proteins which include six high-affinity IGF binding proteins (IGFBP1-6) and at least four low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP).
• The IGFBP members are cysteine- rich proteins with conserved cysteine residues, clustered in the amino-terminal and the carboxy-terminal regions of the molecule.
• Contained within IGFBP-1 and -2 is an integrin receptor recognition sequence (RGD) that is responsible for promoting cell migration by an IGF-independent action.
• IGFBPs hold a central position in IGF ligand-receptor interactions through influences on both the bioavailability and distribution of IGFs in the extracellular environment.
• IGFBPs will either inhibit or enhance the biological activities of IGF or act in an IGF-independent manner.
• IGF-BP7 is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin.
• It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation.
• Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis.
• Recombinant human IGF-BP7 is a 26.4kD protein consisting of 257aa residues.
• IGFBP-RP1 is closely related to CTGF (IGFBP-8), NOV (IGFBP-9) and CYR61 (IGFBP-10).
• The four proteins constitute a subfamily of low-affinity IGFBPs.
• Applications:Suitable for use in ELISA.
• Western Blot, though not tested, may potentially be used as an application.
• Other applications not tested.
• Recommended Dilution:ELISA: 0.5-1ug/mlWestern Blot: 1-3ug/ml using ECL techniqueOptimal dilutions to be determined by the researcher.
• Storage and Stability:Lyophilized powder may be stored at -20°C.
• Stable for 12 months at -20°C.
• Reconstitute with sterile ddH2O or PBS.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20°C.
• Reconstituted product is stable for 12 months at -20°C.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
• Further dilutions can be made in assay buffer.